{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-014934","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.357928+00:00","generated_at":"2026-06-19T20:38:31.889955+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Replimune Q3 net loss $39.7M; cash $616M; RP1 melanoma achieves 36% ORR in IGNYTE cohort","bullets":["Net loss $39.7M for fiscal Q3 ended Dec 31, 2022 vs $29.7M YoY; R&D expenses rose to $30.3M.","Raised ~$259M gross in upsized public offering; secured $200M non-dilutive debt facility ($30M drawn); cash runway into H2 2025.","Topline data from CERPASS trial (RP1+cemiplimab in CSCC) delayed to Q3 2023 from prior H1 2023.","IGNYTE cohort of RP1+Opdivo in anti-PD1 failed melanoma: 36% ORR, 20% CR in first 75 patients; target enrollment of 125 reached.","Collaboration with Roche for RP2/3 in CRC and HCC; appointed Christopher Sarchi as CCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-014934","json":"https://secwatch.observer/filing/0001104659-23-014934.json","markdown":"https://secwatch.observer/filing/0001104659-23-014934.md","text":"https://secwatch.observer/filing/0001104659-23-014934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/0001104659-23-014934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/tm235946d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T20:38:31.889955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62425ef1484d8d10d2ff3ff2131ccd248feb56b2","claim":"Replimune Group, Inc. reported financial results for the fiscal third quarter ended December 31, 2022.","evidence_excerpt":"On February 9, 2023, Replimune Group, Inc. issued a news release announcing its financial results for the third quarter ended December 31, 2022 and certain corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923014934/0001104659-23-014934-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}